Rosiglitazone improves endothelial function in patients with type 2 diabetes treated with insulin
Φόρτωση...
Ημερομηνία
Συγγραφείς
Naka, K. K.
Papathanassiou, K.
Bechlioulis, A.
Pappas, K.
Kazakos, N.
Kanioglou, C.
Papafaklis, M. I.
Kostoula, A.
Vezyraki, P.
Makriyiannis, D.
Τίτλος Εφημερίδας
Περιοδικό ISSN
Τίτλος τόμου
Εκδότης
Περίληψη
Τύπος
Είδος δημοσίευσης σε συνέδριο
Είδος περιοδικού
peer-reviewed
Είδος εκπαιδευτικού υλικού
Όνομα συνεδρίου
Όνομα περιοδικού
Diab Vasc Dis Res
Όνομα βιβλίου
Σειρά βιβλίου
Έκδοση βιβλίου
Συμπληρωματικός/δευτερεύων τίτλος
Περιγραφή
An increased incidence of myocardial infarction with rosiglitazone in patients with type 2 diabetes mellitus (T2DM) has been reported. This study aimed to assess the effect of rosiglitazone on endothelial function, assessed by flow-mediated dilation (FMD), in 34 patients with advanced T2DM treated with insulin without known cardiovascular disease. Patients were randomised into two groups: no additional treatment was given in 17 patients, while 17 patients were given rosiglitazone for 6 months. Addition of rosiglitazone significantly reduced glycosylated haemoglobin (HbA(1c)) (p < 0.0005) and fasting glucose (p < 0.05) and improved FMD (p < 0.005). No significant changes were observed in the insulin-only group. The single independent predictor of FMD improvement was rosiglitazone treatment (p = 0.048). These results show that, in patients with advanced T2DM treated with insulin, addition of rosiglitazone may have a beneficial effect on endothelial function. Further research is needed to investigate why this beneficial effect does not translate into improved cardiovascular prognosis in these patients.
Περιγραφή
Λέξεις-κλειδιά
Aged, Analysis of Variance, Biological Markers/blood, Blood Glucose/drug effects/metabolism, Chi-Square Distribution, Diabetes Mellitus, Type 2/blood/*drug therapy/physiopathology, Drug Therapy, Combination, Endothelium, Vascular/*drug effects/physiopathology, Female, Greece, Hemoglobin A, Glycosylated/metabolism, Humans, Hypoglycemic Agents/*therapeutic use, Insulin/*therapeutic use, Male, Middle Aged, Thiazolidinediones/*therapeutic use, Time Factors, Treatment Outcome, Vasodilation/*drug effects
Θεματική κατηγορία
Παραπομπή
Σύνδεσμος
http://www.ncbi.nlm.nih.gov/pubmed/21576196
http://dvr.sagepub.com/content/8/3/195.full.pdf
http://dvr.sagepub.com/content/8/3/195.full.pdf
Γλώσσα
en
Εκδίδον τμήμα/τομέας
Όνομα επιβλέποντος
Εξεταστική επιτροπή
Γενική Περιγραφή / Σχόλια
Ίδρυμα και Σχολή/Τμήμα του υποβάλλοντος
Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής